Zeng Yancong, Zheng Ziyou, Yin Meili, Li Jiahao, Xu Jun, Tang Yinying, Zhang Kun, Liu Zhijun, Chen Shijian, Sun Pinghua, Chen Heru
Institute of Traditional Chinese Medicine and Natural Products/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
Institute of Traditional Chinese Medicine and Natural Products/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education, College of Pharmacy, Jinan University, Guangzhou 510632, PR China; Guangzhou PharmCherub Medicine & Sci-Tech Incorporated Company, Guangzhou 510700, PR China.
Bioorg Chem. 2023 Feb;131:106300. doi: 10.1016/j.bioorg.2022.106300. Epub 2022 Nov 26.
The primary objective of this study was to investigate the structure-activity relationship of a new series of 5F-like Aldose Reductase Inhibitors (ARIs) using in silico docking method. In this perspective, 6 novel ARIs have been designed and synthesized. Evaluation of the inhibition of these compounds to ALR2 was carried on with epalrestat and 5F as the references. It was found that the spacer of 5F-like ARIs has a great influence on their inhibitory activity. Rigid spacer with length equal to 3 ∼ 4 carbon alkyl chain brings about better inhibitory activity. Among them, compound 4b was verified as the most active ARIs, where its IC value was 16.8 ± 1.3 nM. Furthermore, in silico docking studies using AutoDock 4.2 as well as molecular simulation using GROMACS 2022.1 showed that 5F-like ARIs adopt a dual-occupation mode. The interaction energy (-25 to -74 kcal/mol), as well as MM-GBSA binding free energy (-37 to -65 kcal/mol) was positively correlated with their ALR2 inhibition constant (2000 to 16.8 nM). Docking interaction explained well the structure-activity relationship. A pharmacophore model has been set up for 5F-like ARIs thereafter. This model indicates that as an effective ARI, the entity should have four characteristics: an aromatic center, two hydrogen bond donors, and one hydrogen bond acceptor. By the way, all the 5F-like ARIs reported here are good to mild antioxidant with EC value between 13.6 ± 1.2 and 71.1 ± 3.2 μM. All our data direct the further development of more optimal ARIs for the treatment of diabetic complication in the future.
本研究的主要目的是使用计算机对接方法研究一系列新型5F类醛糖还原酶抑制剂(ARIs)的构效关系。从这个角度出发,设计并合成了6种新型ARIs。以依帕司他和5F为对照,对这些化合物对ALR2的抑制作用进行了评估。发现5F类ARIs的间隔基团对其抑制活性有很大影响。长度等于3至4个碳的烷基链的刚性间隔基团具有更好的抑制活性。其中,化合物4b被证实为活性最高的ARIs,其IC值为16.8±1.3 nM。此外,使用AutoDock 4.2进行的计算机对接研究以及使用GROMACS 2022.1进行的分子模拟表明,5F类ARIs采用双占据模式。相互作用能(-25至-74 kcal/mol)以及MM-GBSA结合自由能(-37至-65 kcal/mol)与其ALR2抑制常数(2000至16.8 nM)呈正相关。对接相互作用很好地解释了构效关系。此后建立了5F类ARIs的药效团模型。该模型表明,作为一种有效的ARIs,该实体应具有四个特征:一个芳香中心、两个氢键供体和一个氢键受体。顺便说一下,这里报道的所有5F类ARIs都是良好至中等的抗氧化剂,EC值在13.6±1.2至71.1±3.2 μM之间。我们所有的数据都为未来开发更优化的ARIs用于治疗糖尿病并发症指明了方向。